# OnCo record nct06384352 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06384352/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06384352", "NCT06384352" ;
  schema:name "Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors"@en ;
  schema:description "A phase 1 trial of YL211 alone in advanced solid tumours and with pembrolizumab in non-squamous non-small-cell lung cancer, run by MediLink Therapeutics (Suzhou) Co., Ltd., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06384352/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06384352> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1" ;
  schema:startDate "2024-05-01" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/>, <https://onco.cc/cancers/nsclc/> ;
  onco:drugs <https://onco.cc/drugs/yl211/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/cisplatin/> ;
  onco:companies <https://onco.cc/companies/medilink/>, <https://onco.cc/companies/roche-genentech/> .